ADTX underwent a dramatic business transformation with revenue collapsing 98% while R&D expenses plummeted 71%, alongside a massive 254% share reduction and fundamental shift in company mission.
The company appears to have pivoted from its previous business model to focus on autoimmune therapeutics, specifically the ADI-100 platform for type-1 diabetes and other autoimmune conditions. The massive reduction in outstanding shares (from 1.16M to 904K) combined with improved cash position suggests a potential reverse split or major restructuring that consolidated ownership while the mission statement completely changed to emphasize "socially owned" healthcare innovation.
ADTX shows extreme financial volatility with revenue nearly disappearing (down 98% to just $3K) while R&D spending was slashed by 71% to $3.2M, suggesting a shift from active operations to early-stage development. Despite operational cash flow worsening to -$25.7M, the company dramatically improved its balance sheet with stockholders' equity surging over 1000% to $5.6M and cash increasing 758% to $833K, indicating significant capital injection or restructuring. The financial profile suggests a company that has essentially restarted with new funding and a completely different business focus.
Equity base grew 1029.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Cash position surged 757.9% — strong cash generation or capital raise providing significant financial cushion.
SG&A up 452.1% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Interest expense surged 170.3% — significant debt increase or rising rates materially impacting earnings.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Revenue declined 97.6% — significant demand weakness or market share loss warrants investigation.
Current assets grew 91.1% — improving short-term liquidity or inventory/receivables build.
Receivables declined — improved collection efficiency or conservative revenue recognition.
R&D spending cut 70.7% — could signal cost discipline or concerning reduction in innovation investment.
Operating cash flow fell 53.3% — earnings quality concerns; investigate working capital changes and non-cash items.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →